Anthropic unveils ‘Claude Science’ for scientific research
FILE PHOTO: Anthropic logo is seen in this illustration taken May 20, 2024. REUTERS/Dado Ruvic/Illustration/File Photo
Read a summary of this article on FAST.
Get bite-sized news via a new
cards interface. Give it a try.
Click here to return to FAST
Tap here to return to FAST
FAST
June 30 : Anthropic on Tuesday launched Claude Science, an AI research workbench, designed to help scientists streamline research, analyze data and manage complex computing workflows.
The workbench offers scientists a user interface specifically designed for conducting research.
The launch is part of Anthropic’s life sciences and healthcare initiative, which the IPO-bound company has been developing since October 2025.
Here are a few details on the launch:
![]()
Guess Word
Crack the word, one row at a time
![]()
Buzzword
Create words using the given letters
![]()
Mini Sudoku
Tiny puzzle, mighty brain teaser
![]()
Mini Crossword
Small grid, big challenge
![]()
Word Search
Spot as many words as you can
• Claude Science combines databases, coding tools, compute and research workflows in one workspace, helping scientists analyze literature, run analyses, create figures and manuscripts, and trace results back to their source code and environment.
• The tool is pre-configured with more than 60 scientific databases and can render scientific artifacts such as 3D protein structures, genome browser tracks and chemistry drawings, Anthropic said.
• Claude Science runs on Anthropic’s existing Claude models, which have undergone the company’s standard responsible scaling and biosecurity evaluations.
• Several research organizations and companies testing the platform in beta reported significant efficiency gains, Anthropic added.
• Anthropic is also launching its own pre-clinical drug programs, focused on neglected diseases, the AI startup’s head of life sciences Eric Kauderer-Abrams said during a press briefing.
• “These are areas that are outside the scope of what the traditional pharma and biotech landscape might consider attractive targets, but nonetheless have real burden associated with them,” Kauderer-Abrams said.
Source: Reuters
Sign up for our newsletters

Get the CNA app
Stay updated with notifications for breaking news and our best stories
Get WhatsApp alerts
Join our channel for the top reads for the day on your preferred chat app

Get bite-sized news via a new
cards interface. Give it a try.
Click here to return to FAST
Tap here to return to FAST
FAST














